CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • STAA Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Reddit

Staar Surgical (STAA)

Company Profile
STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or 'ICL', which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland.
Staar Surgical logo

Company profile

Ticker
STAA
Exchange
NASDAQ
Website
www.staar.com
CEO
Caren Mason
Employees
Incorporated
Delaware
Location
California
Fiscal year end
Dec 30
Sector
Manufacturing > Surgical and Medical Instrument Manufacturing
Industry (SIC)
Ophthalmic Goods
Bausch + Lomb • Alcon Inc. - Registered Shares • National Vision • Warby Parker • RxSight • Cooper Companies • Innovative Eyewear • Luxottica Group Spa ...
Former names
STAAR SURGICAL COMPANY
SEC CIK
0000718937
Corporate docs
Articles of Incorporation & Bylaws
Underwriting Agreements
Plans of Reorganization
Indentures
Material Contracts & Credit Agreements
Subsidiaries Lists
Subsidiaries
STAAR Surgical UK LTD • STAAR Surgical AG • STAAR Japan Inc. • STAAR Surgical PTE. LTD • Technology (Shanghai) Co., LTD • CO., LTD • STAAR Surgical India Private Limited ...
IRS number
953797439

STAA stock data

Analyst ratings and price targets

Last 3 months
Current price
Average target
$77.17
Low target
$60.00
High target
$85.00
Benchmark
Maintains
Buy
$75.00
1 Feb 23
Canaccord Genuity
Maintains
Buy
$80.00
30 Jan 23
Stephens & Co.
Maintains
Overweight
$85.00
28 Dec 22
Stifel
Initiated
Hold
$60.00
8 Dec 22
BTIG
Maintains
Buy
$80.00
3 Nov 22
Needham
Maintains
Buy
$83.00
3 Nov 22
Latest filings (excl ownership)
View all
8-K
Amendments to Articles of Incorporation or Bylaws
1 Feb 23
8-K
STAAR Surgical Reports Preliminary Sales for Fourth Quarter and Fiscal 2022
9 Jan 23
8-K
STAAR Surgical CEO Caren Mason to Retire; Tom Frinzi Appointed New CEO
19 Dec 22
8-K
STAA.OQ - Q3 2022 STAAR Surgical Co Earnings Call
3 Nov 22
10-Q
2022 Q3
Quarterly report
2 Nov 22
8-K
STAAR Surgical Reports Third Quarter Net Sales of $76 Million Up 30% Y/Y
2 Nov 22
8-K
Regulation FD Disclosure
11 Aug 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
8-K
STAAR Surgical Reports Record Second Quarter Net Sales of $81.1 Million Up 30% Y/Y
10 Aug 22
8-K
Departure of Directors or Certain Officers
20 Jul 22
Transcripts
View all
STAA
Earnings call transcript
2022 Q2
11 Aug 22
STAA
Earnings call transcript
2022 Q1
4 May 22
STAA
Earnings call transcript
2021 Q4
24 Feb 22
STAA
Earnings call transcript
2021 Q3
4 Nov 21
STAA
Earnings call transcript
2021 Q2
5 Aug 21
STAA
Earnings call transcript
2021 Q1
6 May 21
STAA
Earnings call transcript
2020 Q4
25 Feb 21
STAA
Earnings call transcript
2020 Q3
4 Nov 20
STAA
Earnings call transcript
2020 Q3
4 Nov 20
STAA
Earnings call transcript
2020 Q2
5 Aug 20
Latest ownership filings
View all
SC 13G/A
BlackRock Inc.
23 Jan 23
SC 13G/A
BAILLIE GIFFORD & CO
19 Jan 23
4
James E Francese
4 Jan 23
4
THOMAS G FRINZI
4 Jan 23
4
NEAL C BRADSHER
29 Dec 22
4
James E Francese
29 Sep 22
4
Keith Holliday
17 Aug 22
3
Robert Studholme
5 Jul 22
4
K Peony Yu
17 Jun 22
4
Elizabeth Yeu Lin
17 Jun 22

Financial summary

Financial statements Chart STAA financial data
Quarter (USD) Sep 22 Jul 22 Apr 22 Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Jan 21 Jan 20 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 129.24 mm 129.24 mm 129.24 mm 129.24 mm 129.24 mm 129.24 mm
Cash burn (monthly) 24.42 mm 5.58 mm (no burn) (no burn) (no burn) (no burn)
Cash used (since last report) 100.81 mm 23.05 mm n/a n/a n/a n/a
Cash remaining 28.43 mm 106.19 mm n/a n/a n/a n/a
Runway (months of cash) 1.2 19.0 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

STAA institutional ownership history Ownership history
13F holders Current Prev Q Change
Total holders 293 265 +10.6%
Opened positions 53 32 +65.6%
Closed positions 25 33 -24.2%
Increased positions 104 118 -11.9%
Reduced positions 99 76 +30.3%
13F shares Current Prev Q Change
Total value 7.82 bn 3.27 bn +139.3%
Total shares 54.07 mm 54.68 mm -1.1%
Total puts 415.40 k 194.80 k +113.2%
Total calls 928.30 k 486.20 k +90.9%
Total put/call ratio 0.4 0.4 +11.7%
Largest owners Shares Value Change
Broadwood Partners 8.59 mm $0.00 0.0%
Broadwood Capital 8.59 mm $606.17 mm 0.0%
BLK Blackrock 5.60 mm $394.83 mm -1.6%
Vanguard 5.22 mm $368.16 mm +1.1%
Baillie Gifford & Co 5.13 mm $361.77 mm -3.0%
Palo Alto Investors 1.10 mm $77.39 mm -0.9%
Geneva Capital Management 947.13 k $66.82 mm +4.2%
Geode Capital Management 870.93 k $61.44 mm +2.3%
E Fund Management 732.30 k $51.66 mm 0.0%
PFG Principal Financial Group Inc - Registered Shares 693.12 k $48.90 mm +26.4%
Largest transactions Shares Bought/sold Change
STT State Street 0.00 -1.56 mm EXIT
MS Morgan Stanley 609.27 k +320.95 k +111.3%
Nicholas Investment Partners 166.32 k +166.32 k NEW
Baillie Gifford & Co 5.13 mm -157.56 k -3.0%
PFG Principal Financial Group Inc - Registered Shares 693.12 k +144.92 k +26.4%
Cinctive Capital Management 0.00 -138.48 k EXIT
Millennium Management 182.80 k +128.41 k +236.1%
Bessemer 163.63 k +112.01 k +217.0%
Lisanti Capital Growth 68.16 k -101.85 k -59.9%
MNGPF Man 95.33 k +95.33 k NEW
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

STAA insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
3 Jan 23 Frinzi Thomas G Common Shares Option exercise Acquire M No No 0 87,805 0.00 92,534
3 Jan 23 Frinzi Thomas G Common Stock Options Common Stock Option exercise Acquire M No No 51.25 160,638 8.23 mm 160,638
30 Dec 22 James E Francese Common Stock Options Common Stock Option exercise Acquire M No No 48.54 19,139 929.01 k 19,139
29 Dec 22 Broadwood Partners Common Stock Buy Acquire P Yes No 0 0 0.00 8,783,082
29 Dec 22 Broadwood Partners Common Stock Buy Acquire P No No 47.9261 39,090 1.87 mm 8,783,082
28 Dec 22 Broadwood Partners Common Stock Buy Acquire P Yes No 0 0 0.00 8,743,992
28 Dec 22 Broadwood Partners Common Stock Buy Acquire P No No 46.9761 100,000 4.70 mm 8,743,992
27 Dec 22 Broadwood Partners Common Stock Buy Acquire P Yes No 0 0 0.00 8,643,992
27 Dec 22 Broadwood Partners Common Stock Buy Acquire P No No 47.9087 51,985 2.49 mm 8,643,992
27 Sep 22 James E Francese Common Stock Sell Dispose S No No 75 13,075 980.63 k 34,908
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro
Benchmark Maintains Buy on Staar Surgical, Lowers Price Target to $75
1 Feb 23
Benchmark analyst Bruce Jackson maintains Staar Surgical (NASDAQ:STAA) with a Buy and lowers the price target from $78 to $75.
Canaccord Genuity Maintains Buy on Staar Surgical, Raises Price Target to $80
30 Jan 23
Canaccord Genuity analyst William Plovanic maintains Staar Surgical (NASDAQ:STAA) with a Buy and raises the price target from $79 to $80.
Analyst Reiterates This Ophthalmology Device Stock On Steep But Attractive Risk/Reward
24 Jan 23
Needham analyst expects the U.S. ICL market of more than $2.4 billion, despite some investors considering the market to be niche, with STAAR Surgical Company (NASDAQ: STAA) becoming a major player in this category over time.
Analyst Expectations for Staar Surgical's Future
20 Jan 23
Canaccord Genuity Maintains Buy on Staar Surgical, Raises Price Target to $79
20 Jan 23

Press releases

From Benzinga Pro
Actress and Beauty Entrepreneur Peyton List Sets Her Sights on 2023 with Upgraded Vision from Life-Changing EVO ICL Lenses
11 Jan 23
Cobra Kai Star Peyton List is the Latest Celebrity Bringing Life Into Focus with EVO ICL Lenses STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses, today
STAAR Surgical CEO Caren Mason to Retire; Tom Frinzi Appointed New CEO
19 Dec 22
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that President and Chief Executive Officer Caren Mason will be retiring December
STAAR Surgical Opens EVO Experience Center in United States
17 Nov 22
Facility Now Serves as a Dynamic Hub of the EVO Lens-Based Experience for Ophthalmic Surgeons, Staff and Healthcare Practitioners STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of
Finsight
Resources
  • Knowledgebase
  • Log In
  • Register
Company
  • About
  • Contact
  • Solutions
Products
  • Deal Roadshow
  • DealVDR
  • Evercall
  • Finsight.com
CapEdge
  • Earnings Calendar
  • Earnings Transcripts
  • EDGAR Filing Screener
  • IPO Calendar
  • Compliance
  • Privacy
  • Security
  • Terms
AngelList LinkedIn